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that depend on GAG length and sulfate moiety position,
whereas ␣-synuclein and A␤ aggregates exhibit more flexible
interactions with HSPGs. These principles may inform the
development of mechanism-based therapies to block transcellular propagation of amyloid protein– based pathologies.

Tau and ␣-synuclein aggregates bind heparan sulfate proteoglycans (HSPGs)3 on the cell surface, which mediate uptake
and intracellular seeding (1). However, the specificity of this
interaction is unknown. Heparan sulfate (HS) is a linear glycosaminoglycan (GAG) composed of disaccharide repeats of
uronic acid (iduronic or glucuronic acid) and glucosamine with
sulfate moieties at discrete N-, C2-, C3-, and C6-residues (Fig.
1) and is synthesized in all known eukaryotic cells (2, 3). Heparin is a linear GAG that is elaborated and secreted by mast cells.
It is chemically similar to HS and frequently used as a model
compound for HS. Heparin differs from HS by shorter average
chain lengths, higher contents of iduronic acid, and a higher
average number of sulfate moieties per disaccharide unit, which
leads to higher charge density per residue (2). HS chains are
covalently attached to core proteins, forming HSPGs. Many
HSPGs are secreted into the extracellular matrix or are membrane-associated either via a transmembrane domain or a glycosylphosphatidylinositol anchor (2, 3). The structure of the HS
chains is determined by the activity of synthetic enzymes, availability of precursor molecules, and flux through the Golgi apparatus. The structural diversity of HSPGs among different cell
and tissue types accounts for their interaction with a myriad of
proteins. The so-called heparan sulfate interactome is composed of proteins involved in cell attachment, migration, invasion and differentiation, morphogenesis, organogenesis, blood
coagulation, lipid metabolism, inflammation, and injury response (2, 4). Some HS-binding proteins bind HS carbohydrates with great specificity. The interaction between HSPGs
3

The abbreviations used are: HSPG, heparan sulfate proteoglycan; HS, heparan sulfate; GAG, glycosaminoglycan; A␤, ␤-amyloid; YFP, yellow fluorescent protein; CFP, cyan fluorescent protein; RD, repeat domain; ANOVA,
analysis of variance; CMV, cytomegalovirus; HBSS, Hanks’ buffered saline
solution; IRES, internal ribosomal entry site; TIDE, tracking of indels by
decomposition; gDNA, genomic DNA; MFI, median fluorescence intensity.
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Transcellular propagation of protein aggregate “seeds” has
been proposed to mediate the progression of neurodegenerative
diseases in tauopathies and ␣-synucleinopathies. We previously
reported that tau and ␣-synuclein aggregates bind heparan sulfate proteoglycans (HSPGs) on the cell surface, promoting cellular uptake and intracellular seeding. However, the specificity
and binding mode of these protein aggregates to HSPGs remain
unknown. Here, we measured direct interaction with modified
heparins to determine the size and sulfation requirements for
tau, ␣-synuclein, and ␤-amyloid (A␤) aggregate binding to glycosaminoglycans (GAGs). Varying the GAG length and sulfation
patterns, we next conducted competition studies with heparin
derivatives in cell-based assays. Tau aggregates required a precise GAG architecture with defined sulfate moieties in the Nand 6-O-positions, whereas the binding of ␣-synuclein and A␤
aggregates was less stringent. To determine the genes required
for aggregate uptake, we used CRISPR/Cas9 to individually
knock out the major genes of the HSPG synthesis pathway in
HEK293T cells. Knockouts of the extension enzymes exostosin
1 (EXT1), exostosin 2 (EXT2), and exostosin-like 3 (EXTL3), as
well as N-sulfotransferase (NDST1) or 6-O-sulfotransferase
(HS6ST2) significantly reduced tau uptake, consistent with our
biochemical findings, and knockouts of EXT1, EXT2, EXTL3, or
NDST1, but not HS6ST2 reduced ␣-synuclein uptake. In summary, tau aggregates display specific interactions with HSPGs

GAG length/sulfation logic for amyloid uptake via HSPGs

Figure 1. Basic disaccharide unit of heparan sulfate and heparin. The
basic disaccharide unit of heparan sulfate and heparin is composed of uronic
acid (glucuronic acid or iduronic acid, left) and glucosamine (right). Iduronic
acid results from epimerization of glucuronic acid. Heparin differs from HS by
shorter average chain lengths, higher contents of iduronic acid, and a higher
charge density per residue. Uronic acid residues are sulfated at the 2-O-position, whereas glucosamine residues are sulfated at the N-, 3-O-, and 6-Opositions (2, 3).

Results
Carbohydrate microarrays identify unique binding patterns
for amyloid proteins
Carbohydrate microarrays allow rapid analysis of interactions between proteins and GAGs (12). We used this approach
to investigate the structural components of heparin that are
required for binding to tau, ␣-synuclein, A␤, and huntingtin
fibrils (Fig. 2). We employed a library of modified heparin polysaccharides (Neoparin, Alameda, CA) to investigate sulfation
requirements for binding: heparin (Hep), N-desulfated heparin

Inhibition of amyloid uptake requires specific heparin
sulfation
We and others have previously observed that heparin inhibits the cellular binding and uptake of tau, ␣-synuclein, and A␤
(1, 7). Heparin directly interacts with HS binding domains
and prevents aggregate binding to HSPGs on the cell surface.
Thus, we tested whether the structural determinants of the
aggregate–GAG interaction observed in the microarray assay
would translate to aggregate internalization and propagation in
cells.
We labeled tau, ␣-synuclein, and A␤ fibrils with a fluorescent
Alexa Fluor 647 dye and applied them to C17.2 cells in culture
for 4 h (tau and ␣-synuclein) or 20 h (A␤), optimal times determined empirically. We measured aggregate uptake with flow
cytometry by quantifying the median fluorescence intensity
(MFI) per cell. Heparin decreased seed internalization dosedependently for all three fibril types (Fig. 3).
We next tested the desulfated heparins as inhibitors of aggregate internalization (Fig. 4). Tau aggregate uptake was strongly
inhibited by 2-O-desulfated heparin, similar to standard heparin. Thus, removal of 2-O-sulfates did not disrupt tau uptake
inhibition. The inhibitory potency of 6-O-desulfated heparin
was reduced compared with 2-O-desulfated heparin and standard heparin, whereas N-desulfated heparin had virtually no
inhibitory effect (Fig. 4). In summary, as for heparin binding in
vitro, competitors for tau uptake in cells required 6-O- and
N-sulfation, whereas 2-O-sulfation was dispensable.
J. Biol. Chem. (2018) 293(27) 10826 –10840
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and their binding proteins can depend on modification,
domain, charge, and sugar conformation (2, 5, 6). Some interactions are based on defined chemistry. For example, the binding of a protein may require spatially separated patches of sulfated residues on the GAGs. Purely charge-based associations
are more flexible, as they are based on electrostatic interactions
between the positively charged residues on the binding protein
and the negatively charged sulfate residues on the HS chain (2).
We do not know whether the interactions of tau and ␣-synuclein with HSPGs are specific to sulfation positioning or are
purely based on charge density.
We previously observed that exogenously applied tau and
␣-synuclein aggregates bind to HSPGs on the cell surface to
trigger cellular uptake and induce intracellular seeding (1).
Thus, the HSPG–aggregate interaction may represent a critical
step for the spread of pathology in neurodegenerative diseases.
Other laboratories have similarly observed that A␤ and prion
protein bind to HSPGs on the cell surface to trigger their internalization (7–11). It is not clear which HSPG properties drive
the interaction with aggregates, and if the required GAG composition for binding differs among amyloid proteins.
We have analyzed the GAG-binding requirements for
recombinant tau, ␣-synuclein, and A␤-amyloid fibrils. We used
a small heparin mimetic library to determine the critical size
and sulfation requirements for HS to bind to aggregates in biochemical and cell-based assays and CRISPR/Cas9 knockout to
test specific components of the HSPG synthesis pathway. Binding of tau fibrils to HSPGs depends on relatively specific modifications, whereas binding of ␣-synuclein and A␤ fibrils
seemed to be more complex and variable between different
experimental approaches.

(De-N), 6-O-desulfated heparin (De-6-O), 2-O-desulfated heparin (De-2-O), O-desulfated heparin (De-O), fully desulfated
heparin (De-S, in which ⬎90% of all sulfates are removed) and
oversulfated heparin (Over-S, which contains ⬎3.5 sulfates per
disaccharide unit).
We applied nanoliter volumes of heparins at concentrations
from 0.5 to 15 M to glass microarray surfaces coated with
poly-L-lysine. We then applied biotinylated full-length tau,
␣-synuclein, A␤42, and huntingtin exon 1 (HttExon1Q50)
fibrils to the microarray, and we visualized the bound proteins
with an anti-biotin antibody tagged with Cy5. Tau, ␣-synuclein,
and A␤ aggregates bound heparin in a concentration-dependent manner (Fig. 2). Huntingtin fibrils exhibited no binding
(data not shown) and were not analyzed further. None of the
fibrils bound desulfated heparin, suggesting that sulfation is
a critical component of the aggregate–GAG interaction (Fig.
2). Our results agreed with previous reports that tau, ␣-synuclein, and A␤, but not Htt, are heparin-binding proteins
(1, 7, 13, 14).
The different seeds exhibited unique sulfation requirements
for binding. Tau efficiently bound heparin and 2-O-desulfated
heparin, whereas 6-O-desulfation, N-desulfation, or O-desulfation abolished its binding (Fig. 2). ␣-Synuclein and A␤ fibrils
each required O-sulfation for heparin binding. However, the
removal of N-, 6-O-, or 2-O-sulfation did not significantly
inhibit their binding, whereas desulfated heparin abolished
their binding (Fig. 2). Thus, for ␣-synuclein and A␤ fibrils, no
single sulfate moiety but overall sulfation was required to mediate binding to the GAG microarray.

GAG length/sulfation logic for amyloid uptake via HSPGs

The structural requirements differed for the inhibition of
␣-synuclein and A␤ (Fig. 4). Compared with standard heparin,
removal of N-sulfation strongly reduced the inhibitory activity
of the compounds on aggregate uptake. The removal of 6-O- or
2-O-sulfation from heparin also reduced its inhibitory effect on
␣-synuclein and A␤ uptake compared with unmodified heparin. Thus, N-sulfation was critical, but other sulfates also contributed to aggregate binding. This result corroborated the
microarray data in that all sulfate moieties seemed to contribute to aggregate binding to GAGs. However, the relevance of
N-sulfation was different between these two experimental
approaches, with no alteration of binding by the removal of
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N-sulfation in the microarray setting and a critical loss of
uptake inhibition in the uptake assay.
Inhibition of aggregate uptake requires a critical chain length
To determine the role of polysaccharide chain length, we
tested the inhibitory activity of fractionated heparins in the cell
uptake assay. Heparin fragments composed of 4, 8, 12, and 16
sugar molecules (referred to as 4-, 8-, 12-, and 16-mer, respectively) were incubated with labeled aggregates, applied to C17.2
cells, and tested for inhibition of uptake (Fig. 5). For tau, shorter
heparin fragments (4- and 8-mer) had no activity, whereas the
longer fragments (12- and 16-mer) modestly inhibited uptake

Downloaded from http://www.jbc.org/ at Washington University on November 18, 2019

Figure 2. Carbohydrate microarray analyses identify unique amyloid–GAG interactions. Biotin-labeled tau, ␣-synuclein, and A␤ fibrils at 1 M (monomer
equivalent) were applied to a glass surface coated with heparin derivatives at 0.5, 1, 5, 10, and 15 M (left to right): heparin (Hep), oversulfated heparin (Over-S),
fully desulfated heparin (De-S), O-desulfated heparin (De-O), N-desulfated heparin (De-N), 2-O-desulfated heparin (De-2-O), and 6-O-desulfated heparin (De-6O). We applied an anti-biotin IgG antibody conjugated to Cy5 and quantified relative fibril binding by measuring fluorescence. Each protein was analyzed in
triplicate, and the data represent an average value for 10 spots at a given carbohydrate concentration. The average values were standardized to the highest
concentration of heparin (15 M) in each data set. Note distinct binding patterns for N-desulfated heparin, 2-O-desulfated heparin, and 6-O-desulfated heparin.
Error bars show S.E.

GAG length/sulfation logic for amyloid uptake via HSPGs

(Fig. 5). No compound had a potency similar to full-length heparin (⬃50-mer), even when taking into account the number of
individual saccharide units. We concluded that larger heparin
chains were necessary to inhibit tau uptake.
A␤ fibrils exhibited greater sensitivity to shorter polysaccharides, and 12- and 16-mer inhibited uptake. As for tau, the
uptake inhibition of A␤ increased with the heparin chain
length. ␣-Synuclein aggregates were also dose-dependently
inhibited by all fractionated heparins, with greater inhibitory
activity of the 12- and 16-mer compared with the shorter heparins (Fig. 5). Thus, depending on their target, heparins required
critical and distinct chain lengths to function as uptake inhibitors. We concluded that tau, ␣-synuclein, and A␤ aggregates
each have specific structural determinants for GAG binding,
including sulfation pattern and size.
Structural requirements for inhibition of seeding
Amyloid aggregates could gain entry to cells by multiple
mechanisms, some of which could lead to seeding activity, and
others not. Thus, we tested heparins in an established seeding
assay that consists of a monoclonal “biosensor” cell line that
stably expresses tau repeat domain (RD) harboring the diseaseassociated mutation P301S (Fig. S1), fused to yellow or cyan
fluorescent proteins (RD-CFP/YFP) (15, 16). Upon binding to
the cell surface, tau aggregates trigger their own internalization
and induce intracellular aggregation of RD-CFP/YFP, enabling
fluorescence resonance energy transfer (FRET). We used flow
cytometry to quantify the number of cells exhibiting FRET. An
␣-synuclein biosensor that expresses full-length ␣-synuclein
with the disease-associated mutation A53T tagged to either
CFP or YFP (syn-CFP/YFP) functioned similarly (16). We did
not test for A␤ seeding due to the lack of a functional biosensor
cell line. We incubated tau or ␣-synuclein fibrils overnight with
heparins, prior to direct exposure of the biosensor cells and
incubation for 48 h. To improve yield (due to low seeding efficiency) we re-exposed the ␣-synuclein biosensor cell line to
aggregate– heparin complexes after passaging for an additional
48 h prior to flow cytometry. Simultaneous application of heparin with tau and ␣-synuclein fibrils to the biosensor cell lines
reduced seeding dose-dependently (Fig. 6).

HSPG synthetic genes required for uptake of aggregates
The HSPG synthesis pathway is a complex hierarchical
cascade taking place in the Golgi apparatus, involving ⬃30
enzymes. After initial formation of a linkage region, extension
enzymes (EXT1 and EXT2) catalyze the addition of alternating
units of glucuronic acid and GlcNAc. The dual activity enzyme
N-deacetylase/N-sulfotransferase then catalyzes N-deacetylation and N-sulfation of some GlcNAc residues. Next, a variable
number of glucuronic acid residues are epimerized to iduronic
acid (2, 3). Finally, sulfate groups are attached to C3 and C6 of
glucosamine and C2 of iduronic acid and some glucuronic acid
residues (Fig. 1) (2, 3). The final structure of the HS chain in
terms of length, sugar composition, and sulfation pattern varies
substantially between different cell and tissue types. We tested
specific genes in the synthesis pathway to elucidate the structural determinants of cell-surface HSPGs and to further test
the requirement of specific sulfation patterns for aggregate
internalization.
We used CRISPR/Cas9 to individually knock out all the genes
in the HSPG synthesis pathway and screened for inhibition of
aggregate uptake in HEK293T cells (Table 1). We selected 5– 6
separate human gRNAs for each gene and cloned them into the
lentiCRISPRv2 vector (17). Plasmids containing the gRNAs for
each gene were pooled and used for lentivirus production. Cells
were exposed to lentivirus and cultured for at least 10 days
under puromycin selection prior to phenotypic screening. As a
positive control, we included the gRNAs to target the valosincontaining peptide (VCP) gene, because the knockout of this
gene is lethal in mammalian cells. In addition, we transduced
the available gRNAs individually to identify the functional
gRNAs for selected genes. We then used a single gRNA to produce polyclonal knockout cell lines and confirmed the presence
of indels in the predicted DNA regions by Tracking of Indels by
Decomposition (TIDE) (Fig. S3) (18). We tested several comJ. Biol. Chem. (2018) 293(27) 10826 –10840
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Figure 3. Heparin blocks aggregate uptake of Tau, ␣-synuclein, and A␤.
Tau, ␣-synuclein, or A␤ seeds labeled with Alexa Fluor 647 fluorescent dye
were applied to C17.2 cells with increasing doses of heparin (0.2, 2, 20, and
200 g/ml). We quantified aggregate uptake based on the MFI per cell by
flow cytometry. Heparin dose-dependently decreased cellular uptake in all
cases. Each condition was recorded in triplicate, and values represent the
average of three separate experiments. Data reflect uptake relative to the
untreated samples. Error bars show S.D.

We next used the desulfated heparins as competitors in the
seeding assay (Fig. 6). 2-O-Desulfated heparin blocked tau seeding almost as well as heparin, whereas 6-O-desulfated heparin
lost most activity, and N-desulfated heparin lost all activity
against tau seeding. These observations were consistent with
our prior finding that N-sulfation and 6-O-sulfation are important for cellular tau binding and internalization, whereas 2-Osulfation is not. For ␣-synuclein, N-desulfated heparin lost
most of its inhibitory activity. 6-O-Desulfated heparin and 2-Odesulfated heparin also had reduced inhibitory activity compared with standard heparin. This indicated that concordant
with results from our uptake studies, N-sulfation and to a lesser
degree 6-O-sulfation and 2-O-sulfation contributed to the inhibition of ␣-synuclein seeding.
We next tested fractionated heparins (4-, 8-, 12-, and
16-mer). We observed no appreciable inhibitory activity
against tau and only slight inhibitory activity against ␣-synuclein with shorter heparin fragments (4- and 8-mer), and
weak activity with longer fragments (12- and 16-mer) for both
fibril types. The results were qualitatively similar to the uptake
assay, indicating that the inhibitory activity of the heparins
against seeding increased with the saccharide chain length
(Fig. 7).

GAG length/sulfation logic for amyloid uptake via HSPGs
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Figure 4. Heparin-mediated inhibition of aggregate uptake requires specific sulfation patterns. Normal heparin and 2-O-, 6-O-, and N-desulfated forms
were tested as inhibitors of cellular uptake for tau, ␣-synuclein, and A␤ aggregates in C17.2 cells. N- and 6-O-desulfated heparins weakly inhibited and
2-O-desulfated heparins strongly inhibited tau uptake. For ␣-synuclein and A␤, removal of N-sulfation and to a lesser degree 6-O-sulfation and 2-O-sulfation
reduced inhibitor efficacy. Each condition was recorded in triplicate, and values represent the average of three separate experiments. Data reflect uptake
relative to the untreated group. Error bars show S.D.

mercially available antibodies to verify gene knockout, but due
to the low endogenous expression levels of the genes in the
HSPG pathway (The Human Protein Atlas version 18, www.
proteinatlas.org (19, 20) and Fig. S4), we were not able to identify antibodies that reliably detected endogenous protein levels
(data not shown).
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The knockout of five genes strongly inhibited tau uptake:
EXT1, EXT2, EXTL3, NDST1, and HS6ST2. Four of these five
genes (EXT1, EXT2, EXTL3, and NDST1) were also required for
␣-synuclein uptake (Fig. 8, Table 2, and Fig. S2). We had previously observed that EXT1 is required for cellular uptake of tau
aggregates (1). EXT1 is a glycosyltransferase that polymerizes

GAG length/sulfation logic for amyloid uptake via HSPGs

heparan sulfate chains, and knockout of the EXT1 gene reduces
HSPG expression without affecting other proteoglycan subtypes (chondroitin and dermatan sulfate proteoglycans) (21).
EXT1 and EXT2 are co-polymerases, and both are required for
proper HS chain elongation in vivo (22). EXTL3 likewise is a
glycosyltransferase involved in the initiation and the elongation
of the HS chain, and reduced levels create longer HS with fewer
side chains (22).
Both NDST1 and HS6ST2 knockouts substantially reduced
tau aggregate internalization (Fig. 8 and Fig. S2A). NDST1
places N-sulfate groups on glucosamine residues, whereas
HS6ST2 attaches sulfate groups to 6-O-glucosamine residues.
NDST1 is a dual activity enzyme with N-acetylase/N-sulfotransferase activity and is located upstream of other sulfotransferases. N-Sulfation is therefore a key regulatory step for subsequent modifications (3), and the knockout of this enzyme is

likely to induce changes of other sulfate moieties as well. However, in conjunction with our previous data that demonstrated a
loss of uptake inhibition by removal of N-sulfates and 6-Osulfates, we concluded that N- and 6-O-sulfate moieties are
critical for HSPG-mediated uptake of tau aggregates. On the
contrary, knockout of genes coding for 2-O- and 3-O-sulfotransferases had no effect (e.g. HS2ST1 and HS3ST3A1) on
tau uptake. Importantly, gRNAs targeting genes for CSPG
synthesis enzymes (CSGALNACT and CHSY1) did not affect
tau uptake (Fig. 8).
For ␣-synuclein, only knockout of NDST1 strongly reduced
aggregate uptake (Fig. 8 and Fig. S2B). Knockout of other sulfotransferases mildly reduced uptake (e.g. HS2ST1), increased
uptake (e.g. HS6ST2, albeit not significantly), or had no effect
(Fig. 8). Consistent with the cell uptake and seeding data,
enzymes responsible for N-sulfation were important for ␣-syJ. Biol. Chem. (2018) 293(27) 10826 –10840
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Figure 5. Inhibition of aggregate uptake requires a critical heparin size. The 4-, 8-, 12-, and 16-mer heparins were evaluated as inhibitors of tau, ␣-synuclein, and A␤ aggregate internalization in C17.2 cells. Potency increased with the GAG chain length. Each condition was recorded in triplicate, and values
represent the average of three separate experiments. Data reflect uptake relative to the untreated group. Error bars show S.D.

GAG length/sulfation logic for amyloid uptake via HSPGs

nuclein uptake, whereas those responsible for sulfation at other
positions did not play a critical role. No gene knockouts
reduced the internalization of labeled transferrin, which is controlled by clathrin-mediated endocytosis, indicating that our
observed effects were likely specific to macropinocytosis
(Fig. 8).
To confirm specific effects of knockout for the main genes of
interest (EXT1, NDST1, and HS6ST2), we produced knockout
cell lines in HEK293T cells and the 2 FRET biosensors by transiently transfecting the gRNA/Cas9 plasmids (so that they
would eventually be lost) and culturing them for at least 10 days.
We then generated rescue plasmids with the HA-tagged cDNA
followed by internal ribosomal entry site (IRES) and an
mCherry-coding sequence. We used the cDNA plasmids to
produce lentivirus and treated the knockout cell lines for at
least 3 days to drive cDNA expression prior to uptake and seeding experiments (Fig. 9). We performed a Western blot using an
anti-HA antibody to detect plasmid overexpression (Fig. S5).
The bands for EXT1-HA (expected mass ⫽ 87.7 kDa) and
NDST1-HA (expected mass ⫽ 102.4 kDa) were located at the
correct locations (lanes 3 and 5, respectively, in Fig. S5). For
HS6ST2-HA (expected mass ⫽ 70.2 kDa), several bands were
visible between ⬃60 and 100 kDa, possibly due to protein
aggregation or changes of protein properties due to the HA tag.
We only detected HA tag in cells overexpressing the rescue
constructs.

10832 J. Biol. Chem. (2018) 293(27) 10826 –10840

Discussion
Using a combination of biochemical and cell-based assays,
we have investigated the HSPG structure–function relationships that govern the uptake of tau, ␣-synuclein, and A␤ aggregates. The aggregate–GAG interaction, especially for tau, is
determined by the pattern of sulfate moieties and the GAG
length. We corroborated our findings with a genetic candidate
screen of the HSPG synthesis pathway and identified specific
sulfotransferases that play a role in tau and ␣-synuclein uptake.
Our data indicate that the interaction between HSPGs and
aggregates may be a regulated and specific biological process.
Distinct sulfation requirements for aggregate binding
We originally employed a library of modified heparin polysaccharides spotted on a microarray to determine that the binding
of tau aggregates depended on 6-O- and N-sulfation, whereas
␣-synuclein and A␤ aggregate binding depended on overall sulfation. We tested predictions from these studies in cell-based
uptake and seeding assays, using heparins as competitive inhibitors of aggregate binding to the cell surface. All data consistently indicated a requirement of N- and 6-O-sulfation for tau
aggregate binding, uptake, and seeding.
In contrast, for ␣-synuclein and A␤ fibrils, the removal of N-,
6-O-, or 2-O-sulfation did not significantly inhibit their binding
to the microarray, indicating that no single sulfate moiety but
overall sulfation was required to mediate binding in this experimental approach. In the uptake experiments, ␣-synuclein and
A␤ aggregate uptake strongly required N-sulfation, whereas
2-O-sulfation and 6-O-sulfation were moderately required. We
observed the same binding pattern for ␣-synuclein seeding.
Thus, although N-sulfation seemed to be more relevant in the
cell-based assays, the microarray data and the cell data congruently showed that all three sulfate moieties play a role for ␣-synuclein and A␤ internalization. Interestingly, a recent report by
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Figure 6. Sulfation pattern specifies inhibition of seeding. 2-O-, 6-O-, and
N-desulfated heparins were evaluated for inhibition of tau seeding in the
P301S FRET biosensor cell line and ␣-synuclein seeding in the A53T FRET
biosensor cell line. We used flow cytometry to quantify seeding based on the
percentage of FRET-positive cells. Inhibition of tau seeding required N-sulfation and, to a lesser extent, 6-O-sulfation. By contrast, ␣-synuclein primarily
required N-sulfation and 6-O- and 2-O-sulfation to a lesser degree. In every
experiment, each condition was tested in triplicate. Values represent the
average of three separate experiments for tau, and two separate experiments
for ␣-synuclein. The data reflect seeding relative to the untreated group. Error
bars show S.D.

Next, we used the knockout and rescue cell lines for uptake
and seeding experiments (Fig. 9). We gated for mCherry-expressing cells and quantified uptake and seeding within this
population. Knockout of all three genes was partly or fully
reversible for tau uptake and seeding when rescued with cDNA
lentivirus (Fig. 9). Similarly, knockout of EXT1 and NDST1 was
partly or fully reversible for ␣-synuclein uptake and seeding.
HS6ST2 knockout increased ␣-synuclein uptake, similar to our
previous data (Fig. 8, albeit not significant here), and did not
change ␣-synuclein seeding. HS6ST2 overexpression decreased
␣-synuclein uptake, yet paradoxically increased seeding. We
concluded that HS6ST2 modulation has complex effects on
␣-synuclein uptake and seeding possibly related to dysregulation/compensation by multiple pathways.
In summary, targeted genetic knockout of the HSPG biosynthesis pathway indicated that both tau and ␣-synuclein internalization were mediated by HSPGs and dependent on specific
sulfotransferases. In concordance with microarray and heparin
competition experiments, tau uptake seemed to depend
strongly on N- and 6-sulfation via NDST1 and HS6ST2. By
contrast, ␣-synuclein uptake depended strongly on N-sulfation
by NDST1 and to a lesser degree on 2-O-sulfation by HS2ST1.

GAG length/sulfation logic for amyloid uptake via HSPGs

Table 1
Genes included in the genetic screen
Major genes involved in the synthesis of HSPGs were screened for effects on tau and
␣-synuclein uptake. We also tested genes coding for proteoglycans core proteins
(glypicans, syndecans) and SULF1/2, which diminish HSPG sulfation via arylsulfatase and endoglucosamine-6-sulfatase activities. Genes involved in the synthesis of
the chondroitin proteoglycan (CSPG) synthesis pathway, as well as SQSTM1, were
targeted as negative controls. To confirm gene knockout we targeted VCP, whose
knockout is lethal after 5 days.

Ihse et al. (23) found that the general degree of sulfation drove
cellular ␣-synuclein uptake rather than specific modifications
within the GAG chain. By contrast, another study demonstrated that baculovirus uptake exhibits specificity similar to
tau, requiring N- and 6-O-sulfation, but not 2-O-sulfation, for
binding and entry into mammalian cells (24).
Zhao et al. (25) recently described a requirement of 6-Osulfation for tau binding to GAGs in vitro, and Rauch et al. (26)
identified a requirement for 6-O-sulfation for tau internalization in induced pluripotent stem cell-derived neurons and
mouse brain slice culture. Differences in the observed importance of N-sulfation could derive from individual protein preparations, cell types, and assays. Given the variations in fibril
structure that can occur during formation in vitro, it is possible
that this could also play a role, as we have previously observed
distinct patterns of neuronal vulnerability to different tau
strains, which are composed of distinct fibrillar structures
(27, 28).
GAG chain length is critical
GAG chain length appears critical to mediate aggregate
binding and uptake of all amyloids studied, although we did
observe differences. Short heparin fragments (4- and 8-mer)
exhibited no inhibitory activity for tau, whereas the longer
fragments (12- and 16-mer) had only low inhibitory activity.
By contrast, A␤ and ␣-synuclein aggregates displayed some
degree of dose-dependent inhibition for all fractionated
heparins, with increasing inhibitory activity for longer fragJ. Biol. Chem. (2018) 293(27) 10826 –10840
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Figure 7. GAG size specifies inhibition of seeding. The potency of different heparins against tau seeding in the P301S FRET biosensor cell line and
␣-synuclein seeding in the A53T FRET biosensor cell line depended on the chain lengths of the heparins. The 4-, 8-, 12-, and 16-mer heparins were evaluated
as inhibitors of tau and ␣-synuclein seeding. The inhibitory potency of the heparin fragments increased with GAG chain length. In every experiment, each
condition was tested in triplicate. Values represent the average of three separate experiments for tau, and two separate experiments for ␣-synuclein. Data
reflect seeding relative to the untreated group. Error bars show S.D.
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Figure 8. HSPG genes critical for the internalization of tau and ␣-synuclein aggregates. Genes implicated in HSPG synthesis were individually targeted in
HEK293T cells using CRISPR/Cas9 to create polyclonal knockout lines. The cell lines were then tested for internalization of fluorescently labeled tau and
␣-synuclein aggregates by measuring MFI per cell with flow cytometry. The cells were treated in parallel with fluorescently labeled transferrin to control for
nonspecific reduction of clathrin-mediated uptake. Knockout of four genes (EXT1, EXT2, EXTL3, and NDST1) reduced both tau and ␣-synuclein uptake, whereas
the knockout of HS6ST2 only reduced tau uptake. None of the gene knockouts reduced transferrin uptake. Data were collected in duplicate on 2 different days
for each cell line and each aggregate type and normalized to uptake from control cells treated with scrambled gRNA (Sc). For transferrin uptake, the data from
all 4 experimental days was combined. Red columns indicate the gene knockouts with the strongest effects. Error bars show S.D. For statistical analyses, we
combined the averages for each experimental day. ****, p ⬍ 0.0001; ***, p ⬍ 0.001; **, p ⬍ 0.01; one-way ANOVA, Dunnett.

ments. We conclude that chain length requirements for
binding will vary among amyloid proteins, although all three
protein aggregates appear to bind longer chains with greater
avidity.
Specific sulfotransferases required for uptake
After screening all HSPG candidate genes, we observed that
knockout of only five genes (EXT1, EXT2, EXTL3, NDST1, and
HS6ST2) strongly reduced tau aggregate uptake. We had previously validated EXT1 as a modifier of tau uptake (1). EXT2,
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EXTL3, NDST1, and HS6ST2 have not previously been recognized to play a role in tau aggregate uptake. EXT2 and EXTL3
have similar functions to EXT1, whereas NDST1 mediates
N-deacetylation/N-sulfation, and HS6ST2 mediates 6-O-sulfation. Knockout of HS2ST1, the sole sulfotransferase for 2-Osulfation, did not alter tau uptake. Taken together, the genetic
data corroborate the microarray and pharmacological data that
tau uptake is mediated by N- and 6-O-sulfation of HSPGs.
For ␣-synuclein, the knockout of EXT1, EXT1, EXTL3, and
NDST1, but not HS6ST2, clearly reduced uptake. Knockout of

GAG length/sulfation logic for amyloid uptake via HSPGs
Table 2
Genes required for tau and ␣-synuclein uptake

The knockout of the listed genes reduced aggregate uptake by ⬎50% and was statistically significant with p ⬍ 0.001 for tau and p ⬍ 0.0001 for ␣-synuclein in the
genetic candidate screen (Fig. 8); One-way Anova, Dunnett.

Conclusion
Our results indicate considerable specificity for tau aggregate
interaction with HSPGs. This relationship is not simply based
on charge density but on the position of sulfate moieties as well.
Thus, further studies to investigate the structural parameters
governing aggregate uptake in vivo could be fruitful. A large
body of literature indicates that sulfated GAGs inhibit the
infectivity of the prion protein in vitro and in vivo (8, 30 –32),
and our data suggest that these concepts might also be applied
to guide drug treatment for other amyloid disorders, such as
tauopathies and ␣-synucleinopathies.

Heparin polysaccharide suppliers
The first experiment with microarrays was performed with
heparins from Neoparin (Alameda, CA), which went out of
business upon completion of the first part of our studies. Therefore, the heparins for the following studies were purchased
from AMSbio (Cambridge, MA). The glycochemistry of these
molecules is complicated, and the quality of the products
depends on the origin of the raw material used, the synthesis
methods, and the final purity of the preparations. We noticed
differences in inhibitory activity when performing uptake
assays with the same heparin from two different companies.
However, we still derived qualitatively similar results, e.g. that
certain defined moieties such as N-sulfation and 6-O-sulfation
are crucial for tau uptake. Also, not all the heparins used in the
microarrays were available from AMSbio, which limited the
number of heparins that could be tested in the second part of
this study.
Carbohydrate microarrays
As described previously (12), solutions of the polysaccharides (10 l per well in a 384-well plate) were spotted onto
poly-L-lysine– coated slides by using a Microgrid II arrayer
(Biorobotics; Cambridge, UK) at room temperature and 50%
humidity. We used solution concentrations between 0.5 and 15
M, and the arrayer printed 1 nl of each concentration 10 times.
The arrays were incubated in a 70% humidity chamber overnight, followed by storage in a low-humidity, dust-free desiccator. For protein binding studies, the slides were blocked with 3%
bovine serum albumin (BSA) in PBS (5 ml) with gentle rocking
at 37 °C for 1 h. Recombinant tau and ␣-synuclein fibrils were
biotinylated with EZ-LinkTM Sulfo-NHS-Biotin biotinylation
kit (ThermoFisher Scientific) according to the manufacturer’s
instructions, lyophilized, and stored at ⫺80 °C until use. BiotinJ. Biol. Chem. (2018) 293(27) 10826 –10840
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HS2ST1 mildly reduced ␣-synuclein uptake, and knockout of
HS6ST2 slightly increased uptake and did not change ␣-synuclein seeding. The overexpression of HS6ST2 decreased
␣-synuclein uptake and paradoxically increased ␣-synuclein
seeding. Thus, the genetic data suggest that N-sulfation, and
to a lesser degree 2-O-sulfation, is important for uptake. The
genetic data partly corroborate the pharmacological data in
that N-sulfation is more relevant for ␣-synuclein uptake and
seeding than the other moieties. However, no alteration of
binding was observed upon removal of single sulfate moieties in the microarray setting. We conclude that binding
of ␣-synuclein to HSPGs is more complex than for tau
and shows some variability between different experimental
approaches.
No other N- and/or 6-O-sulfotransferases were required for
␣-synuclein and tau uptake. Some of the paralogs (e.g. NDST3,
NDST4, and HS6ST3) have low or nondetectable expression
levels in HEK293 cells (The Human Protein Atlas version 18
(19, 20)). It is possible that each paralog possesses unique substrate specificities and is not compensated by other members of
the HSPG family (e.g. NDST2 and HS6ST1). In addition, in the
mammalian brain, the HSPG composition varies substantially
between different brain areas, cell types, and developmental
stages, and little is known so far on the relevance of specific HS
sulfation patterns (29). Thus, in future studies, it will be informative to determine which paralogs drive N- and 6-O-sulfation in
different cell and tissue types. We also recognize that future
work must evaluate the requirements for the genes identified in
this study in the context of post-mitotic central nervous system
neurons.

Materials and methods
Protein preparation, fibrillization, and labeling
Recombinant full-length WT tau and ␣-synuclein were purified and fibrillized as described previously (1). Huntingtin protein (Exon1 Gln-50) was prepared by solid-phase synthesis by
the Keck Biotechnology Resource Laboratory at Yale University
and was labeled and fibrillized as described previously (1). Synthetic A␤42 was purchased from Anaspec unlabeled or with a
biotin tag on the N-terminal amino acid. Biotin-A␤42 was
reconstituted in 1% NH4OH, lyophilized, and stored at ⫺80 °C.
Unlabeled A␤42 was reconstituted in 1% NH4OH, diluted in
PBS, and stored at ⫺80 °C. Fibrillization of A␤42 was achieved
by bringing the protein concentration to 100 M (biotin-A␤42)
or 110 M (unlabeled A␤42) in 10 mM HCl and incubating for
24 h at 37 °C. ␣-Synuclein and A␤42 fibrils were dialyzed into
PBS overnight using dialysis cassettes (ThermoFisher Scientific). For uptake assays, fibrils were incubated with Alexa Fluor
647 succinimidyl ester dye (Invitrogen) for 1 h at room temperature (molar ratios monomer/dye ⬃1:12.5 for tau and ⬃1:4 for
␣-synuclein and A␤42), quenched with 100 mM glycine for 1 h
at room temperature, and dialyzed overnight into PBS using
dialysis cassettes (ThermoFisher Scientific) to remove excess
dye. The labeled fibrils were stored at 4 °C until use.
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Figure 9. Rescue of tau and ␣-synuclein uptake and seeding after gene knockout. We generated knockout (KO) cell lines using HEK293T cells for uptake,
the P301S FRET biosensor cell line for tau seeding, and the A53T FRET biosensor cell line for ␣-synuclein seeding for the main genes of interest (EXT1, NDST1,
and HS6ST2) and tested them with and without genetic rescue (R) by lentiviral cDNA. For tau, knockout of all three genes was rescued by overexpression for
both uptake and seeding. For ␣-synuclein, knockout of EXT1 and NDST1 was rescued for uptake and seeding. However, HS6ST2 knockout increased ␣-synuclein
uptake and did not change ␣-synuclein seeding, whereas HS6ST2 overexpression decreased ␣-synuclein uptake and increased seeding. Data were collected
from at least three different experiments in triplicate for tau uptake and seeding and for ␣-synuclein uptake, and from two different experiments for ␣-synuclein seeding. The uptake or seeding in knockout cell lines was normalized to the uptake/seeding detected in scrambled control cells (Sc). Error bars show
S.D. For statistical analyses, we combined the averages for each experiment. n.s., not significant, *, p ⬍ 0.05; **, p ⬍ 0.01; ***, p ⬍ 0.001; ****, p ⬍ 0.0001; one-way
ANOVA, Holm-Šídák testing.

A␤42 was purchased from Anaspec, fibrillized as described
above, lyophilized, and stored at ⫺80 °C until use. The biotinylated fibrils were reconstituted in 1% BSA in PBS, and 50-l
quantities at a concentration of 1–2 M were added to the
slides, followed by incubation in a humidity chamber for 1 h.
Next, the slides were washed five times for 3 min each in PBS (5
ml) while gently rocking. After the washes, the slides were incubated with an anti-biotin IgG antibody conjugated to Cy5 in the
dark with gentle rocking for 1 h (1:5000, Molecular Probes),
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washed with PBS followed by H2O, and then dried under a
gentle stream of N2. All incubations and washes were carried
out at room temperature. The microarrays were analyzed with
a GenePix 5000a scanner at 635 nm for Cy5, and fluorescence
quantification was performed using GenePix 6.0 software with
correction for local background. Each protein was analyzed in
triplicate, and the data represent an average value for 10 spots at
a given carbohydrate concentration. The average values were
standardized to the fluorescence recorded for the highest con-

GAG length/sulfation logic for amyloid uptake via HSPGs
centration of heparin (15 M) in each data set. Statistical significance was determined using ANOVA with post hoc Tukey’s
HSD for individual comparisons; p values ⬍0.05 were considered statistically significant. A similar experiment was performed with biotinylated monomeric tau, ␣-synuclein, A␤, and
huntingtin (data not shown), but no binding could be detected
(data not shown).
Uptake assay for heparin experiments

Seeding assays for heparin experiments
Tau—We previously used HEK293T cells to generate a stable
monoclonal P301S FRET biosensor cell line by overexpressing
tau RD with the disease-associated mutation P301S (Fig. S1),
and tagged at the C terminus with either CFP or YFP to detect
tau seeding (15, 16). The seeding assay was conducted as
described except that biosensor cells were plated at a density of
15,000 cells/well in a 96-well plate. Recombinant tau fibrils
were sonicated for 30 s at an amplitude of 65 (corresponding to
⬃80 watts, QSonica) prior to use. Fibrils (100 nM monomer
equivalent) were preincubated overnight at 4 °C in media containing the heparins at four different concentrations (0.2–200
g/ml). At 20 –30% confluency, the seed– heparin complexes
were applied to the cells in media volumes of 50 l per well, and
cells were incubated for an additional 48 h. We did not use
Lipofectamine to drive internalization of seeds because we
sought to monitor HSPG-mediated uptake and the inhibitory
activity of heparin blocking this process. Cells were harvested
with 0.05% trypsin and post-fixed in 2% paraformaldehyde for
10 min and then resuspended in flow cytometry buffer (HBSS
plus 1% FBS and 1 mM EDTA). The LSRFortessa SORP (BD
Biosciences) was used to perform FRET flow cytometry. We
quantified FRET as described previously (15, 16) with the fol-

Candidate screen using CRISPR/Cas9 knockout and lentiviral
transduction
5– 6 human gRNA sequences per gene were selected from
the GeCKO version 2 libraries (17). For all gRNA sequences not
beginning with guanine, a single guanine nucleotide was added
at the 5⬘-end of the sequence to enhance U6 promoter activity.
DNA oligonucleotides were synthesized by IDT DNA and
cloned into the lentiCRISPRv2 vector (17) for lentivirus production. The plasmids for 5– 6 gRNAs for each gene were
pooled together. Lentivirus was created as described previously
(33): HEK293T cells were plated at a concentration of 1 ⫻ 106
cells/well in a 6-well plate. 18 h later, cells were transiently
co-transfected with PSP helper plasmid (1200 ng), VSV-G (400
ng), and gRNA plasmids (400 ng) using 7.5 l of TransIT-293
(Mirus). 72 h later, the conditioned medium was harvested and
centrifuged at 1000 rpm for 5 min to remove dead cells and
debris. Lentivirus was concentrated 50⫻ using lenti-X concentrator (Clontech) with the concentrated pellet being resuspended in PBS with 25 mM HEPES (pH 7.4). For transduction, a
1:25 to 1:40 dilution of virus suspension was added to HEK293T
cells at a cell confluency of 20% in a 96-well plate. 20 h posttransduction, infected cells were treated with 2 g/ml puromycin (Life Technologies, Inc.) and cultured for an additional 2
days, followed by passaging 1:5 and a second round of virus and
puromycin application. The cells were kept in culture for at
least 10 days after the first lentiviral transduction before using
J. Biol. Chem. (2018) 293(27) 10826 –10840
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C17.2 cells were plated at 4000 cells per well in a 96-well
plate. Fluorescently labeled aggregates (50 nM monomer equivalent) were sonicated for 30 s at an amplitude of 65 (corresponding to ⬃80 watts; QSonica) and preincubated overnight
at 4 °C in media containing the heparins at four different
concentrations (0.2–200 g/ml). The next morning, the
aggregate– heparin complexes were applied to cells for 4 h (tau
and ␣-synuclein) or 20 h (A␤) for internalization in media vehicles of 150 l per well by media exchange. Incubation times
were optimized empirically. Cells were harvested with 0.25%
trypsin for 5 min and resuspended in flow cytometry buffer
(HBSS plus 1% FBS and 1 mM EDTA) before flow cytometry.
Cells were counted with the LSRFortessa SORP (BD Biosciences). We determined the MFI per cell to quantify cellular
aggregate internalization. Each experiment was conducted
three independent times with technical triplicates per condition, and a minimum of 2000 single cells was analyzed per replicate. Conditions with single cell counts below 2000 were
excluded from analysis. We determined the average MFI of the
replicates for each condition and standardized to aggregate
uptake without inhibitor treatment within each experiment.
The standardized averages of each condition were then combined for the graphs shown in this paper. Data analysis was
performed using FlowJo version 10 software (Treestar Inc.) and
GraphPad Prism version 7 for Mac OS X.

lowing modification; we identified single cells that were YFPand CFP-positive and subsequently quantified FRET-positive
cells within this population. For each data set, three independent experiments with three technical replicates were performed. For each experiment, a minimum of ⬃10,000 single
cells per replicate was analyzed. Wells with YFP/CFP-positive
cell counts below 5000 cells were excluded from the analysis.
Data analysis was performed using FlowJo version 10 software
(Treestar Inc.) and GraphPad Prism version 7 for Mac OS X.
␣-Synuclein—The monoclonal A53T FRET biosensor cell
line was previously established in our laboratory to detect ␣-synuclein seeding, using HEK293T cells stably expressing fulllength ␣-synuclein with the disease-associated mutation A53T,
and tagged either with CFP or YFP (15, 16). The seeding assay
was performed similarly to the tau seeding assay, except that
biosensor cells were plated at a density of 10,000 cells/well in a
96-well plate. Recombinant ␣-synuclein fibrils (200 nM monomer equivalent) were sonicated for 30 s at an amplitude of 65
(corresponding to ⬃80 watts, QSonica) prior to use. The fibrils
were preincubated overnight at 4 °C in media containing the
heparins at four different concentrations (0.2–200 g/ml). At
20% confluency, the fibril– heparin complexes were applied to
the cells in media vehicles of 50 l per well, and cells were
incubated for 48 h. Cells were then split 1:5 into a new 96-well
plate and incubated overnight. The next day, a second treatment with ␣-synuclein fibril– heparin complexes was performed as above. After an additional 48 h, cells were harvested
for flow cytometry. For the data shown, we performed two
independent experiments, with three technical replicates of
each condition in each case. Data analysis was performed as
described above for tau seeding.

GAG length/sulfation logic for amyloid uptake via HSPGs
them for uptake and seeding experiments. After identification
of the genes of interest, we made knockout cell lines using the
available gRNAs individually to identify the functional gRNAs.
We identified 2–3 gRNAs per gene and used these for further
knockout experiments.
Confirmation of gene editing by TIDE (18)
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The uptake assay for the knockout screen was conducted as
described above with the following modifications. Knockout
cell lines were plated at 20,000 cells per well in a 96-well plate.
The next day, aggregates labeled with Alexa Fluor 647 were
sonicated for 30 s at an amplitude of 65 (corresponding to ⬃80
watt, QSonica), mixed with transferrin labeled with Alexa Fluor
488 (Life Technologies, Inc.), and applied to the cells in a vehicle of 50 l of media for 4 h. Final concentrations of tau and
␣-synuclein in the media were 25 nM (monomer equivalent)
and of transferrin 25 g/ml. Cells were harvested with 0.25%
trypsin for 5 min and resuspended in flow cytometry buffer
(HBSS plus 1% FBS and 1 mM EDTA) before flow cytometry.
Cells were counted with the LSRFortessa SORP (BD Biosciences). Data were collected from the same cell lines in duplicate
on two different days. For each replicate, ⬃10,000 single cells
were analyzed. Uptake was normalized to the uptake detected
in scrambled control cells. For the analysis, we combined the
averages for each experimental day to determine the multiplicity adjusted p values using one-way ANOVA and Dunnett testing. Data analysis was performed using FlowJo version 10 software (Treestar Inc.) and GraphPad Prism version
7 for Mac OS X.
Making knockout cell lines for rescue experiments
Two to three functional gRNA plasmids identified as described above were pooled and used for transfection. 30,000
HEK293T cells or FRET biosensors cells (for tau and ␣-synuclein seeding) were plated per well in a 96-well plate. The
next day, 100 ng of DNA was combined with OptiMEM (Gibco,
Life Technologies, Inc.) to a final volume of 10 l per well.
Similarly, 0.5 l of Lipofectamine-2000 per well (Invitrogen,
Life Technologies, Inc.) was combined with OptiMEM (Gibco,
Life Technologies, Inc.) to a final volume of 10 l per well in a
master mix solution. Both solutions were mixed after 5 min of
incubation and incubated for an additional 20 min at room
temperature, followed by dropwise addition to the cells at about
70% of cell confluency. We applied puromycin once at 2 g/ml
24 h after transfection. Cells were cultured to confluency, passaged, and transfected in a similar way two more times. Cells
were maintained in culture at least 10 days after the last transfection and prior to uptake and seeding experiments.
Cloning for rescue experiments
We used our previously described lentiviral FM5-YFP plasmid (27), replaced the human ubiquitin C promoter with a
human CMV promoter, replaced the YFP sequence with an
HA-tag coding sequence, and added an IRES element followed
by an mCherry-coding sequence downstream of the insert.
The resulting FM5/HA IRES mCherry vector bicistronically
expresses an HA-tagged insert and mCherry protein from the
same promoter. For the rescue experiments, EXT1 (pCMV3Ext1-HA; Sino Biological), NDST1 (pUC75-NDST1; Genscript), and HS6ST2 (pANT7-cGST-HS6ST2; DNASU Plasmid
Depository, Arizona State University (35)) cDNA was subcloned into the FM5/HA IRES mCherry vector using Gibson
assembly Master Mix (New England Biolabs) according to the
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We used a single functional gRNA for each gene to produce
knockout cell lines for analysis by TIDE as established by Brinkman et al. (18) to confirm the presence of indels in predicted
DNA regions (Table S1 and Fig. S3). We extracted genomic
DNA using a protocol by Mendell and co-workers (34) with the
following modifications: cell pellets from knockout cell lines
and scrambled control cells (106 cells per sample) were frozen
overnight at ⫺80 °C, thawed the next day, and resuspended in
500 l of tissue lysis buffer (500 l of 10⫻ STE buffer (10 mM
EDTA (pH 8.0), 100 mM Tris-HCl (pH 8.0), 1 M NaCl), 100 l of
0.5 M EDTA, 50 l of 20 mg/ml proteinase K solution (ThermoFisher Scientific), 200 l of 10% SDS, 4.15 ml H2O) and incubated for 5 h with shaking at 550 rpm and 55 °C. Tubes were
allowed to cool down before adding 1 l of 10 mg/ml RNase A
(ThermoFisher Scientific), followed by incubation at 37 °C for
1 h while shaking at 550 rpm. Extractions were performed in
Phase Lock Gels Light (VWR) using 500 l of pH 7.9-buffered
phenol (ThermoFisher Scientific), followed by phenol/chloroform/isoamyl alcohol (ThermoFisher Scientific), followed by
chloroform (Sigma). Each extraction step was followed by centrifugation at 16,000 ⫻ g for 5 min. The upper aqueous phase
was then transferred into a new 2-ml tube, mixed with 1.3 l of
glycoblue, followed by 1 ml of 100% ethanol. The DNA was
precipitated at ⫺80 °C for 1 h, followed by centrifugation at
15,000 ⫻ g for 15 min at 4 °C. Pellets were washed with 1 ml of
75% ethanol, centrifuged again (15,000 ⫻ g, 15 min, 4 °C), dried
for a few minutes at room temperature, and solubilized in 50 l
of water at room temperature for 30 min. DNA concentration
was determined with a spectrophotometer (DeNovix DS-11
FX⫹). PCR primers were designed according to the developer’s
instructions for TIDE (18). PCRs were performed using 100 –
500 ng of genomic DNA with 2⫻ Taq-Pro Red Complete
Polymerase (Denville Scientific, Inc.) following the manufacturer’s instructions. PCR conditions were 3 min at 95 °C (1⫻),
followed by 15 s at 95 °C, 15 s at 55 °C, and 1 min at 72 °C (30⫻)
and 10 min at 72 °C (1⫻). The PCR product was run on a 1%
agarose gel to verify the product size and gel-extracted using the
QIAQuick gel extraction kit (Qiagen). Purified PCR samples
(12 l, ⬃4 – 8 ng/l) were Sanger sequenced at the sequencing
core facility at UT Southwestern Medical Center, Dallas. TIDE
analysis was performed according to the software instructions
(Table S1 and Fig. S3). The data were derived with a forward
primer for HS6ST2 and reverse primers for EXT1 and NDST1.
Because Brinkman et al. (18) found that the results of TIDE
analysis are nearly identical for both DNA strands, we did not
sequence the opposite strands. R2 represents the goodness of fit
and should be close to 0.9 for reliable data (18). R2 was slightly
lower for EXT1 and HS6ST2, but the aberrant sequence signal
was clearly visible in each graph (Fig. S3).

Uptake assay for knockout screen
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manufacturer’s instructions. All genes were sequenced before
use.
Rescue experiments

Western blotting to confirm overexpression of rescue plasmids
The HEK293T knockout cell lines and the scrambled control
cell line were grown to confluency in a 6-well cell culture dish (1
well per cell line). Cells were pelleted at 1000 rpm, washed with
PBS, and frozen at ⫺80 °C. Pellets were thawed on ice, resuspended in 100 l of lysate buffer (0.05% Triton X-100, protease
inhibitor, PBS), incubated for 10 min at 4 °C while rotating, and
centrifuged for 5 min at 1000 ⫻ g. The supernatant was preserved and quantified for total protein content by the Bradford
assay. Samples were boiled for 5 min with SDS-PAGE sample
buffer, and 10 g of total protein were loaded into a 4 –12%
polyacrylamide gel (NuPAGE). Using electrophoresis, samples
were run for ⬃60 min and transferred to a PVDF membrane
(semi-wet transfer method). After blocking in 5% nonfat dry
milk, membranes were incubated with primary antibody
(1:4000 anti-HA tag antibody-ChIP Grade (ab9110, Abcam)) at
room temperature for 2 h. Following an incubation for 2 h at
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We used the cDNA IRES mCherry constructs to produce
lentivirus and concentrated it 50⫻ as described above. We
applied the lentivirus at a 1:600 dilution to the knockout cell
lines for 3 days prior to uptake and seeding experiments. We
also used higher and lower lentivirus concentrations (dilutions
between 1:160 and 1:2400), which led to toxicity for higher concentrations and reduced the percentage of mCherry-positive
cells at lower concentrations, without significantly improving
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